<DOC>
	<DOC>NCT02337725</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.</brief_summary>
	<brief_title>A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients</brief_title>
	<detailed_description>This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study to evaluate the efficacy and safety of TVP-1012 in Japanese participants with early Parkinson's disease. The study period will consist of a 28-week trial period. The participants who fulfill the inclusion criteria and not meeting any of the exclusion criteria will be enrolled, and randomized in a 1:1 ratio to either the 1 mg of TVP-1012 or the placebo group. In each treatment group, participants will receive either 1 mg of TVP-1012 or placebo once daily in a double-blinded manner.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>The participant has a diagnosis of Parkinson's disease with at least two of the following signs: resting tremor, akinesia/hypokinesia, and muscle rigidity. The participant has a Movement Disorder SocietyUnified Parkinson's Disease Rating Scale (MDSUPDRS) Part II + Part III total score of &gt;=14. The participant has Modified Hoehn &amp; Yahr stage 1 to 3 The participant has the Parkinson's disease diagnosed within 5 years The participant is an outpatient of either sex aged &gt;= 30 and &lt; 80 years. The participant has unstable systemic disease. The participant has MiniMental State Examination (MMSE) score of &lt;= 24 The participant has major depression or severe depression, or any other clinically significant psychiatric disease. The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyraminerich food. The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation). The participant has received transcranial magnetic stimulation within 6 months The participant has received amantadine or anticholinergic medication for &gt;= 180 days. The participant has received selegiline, a levodopacontaining product or dopamine agonist for &gt;= 90 days. The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days. The participant has received a levodopacontaining product, dopamine agonist, amantadine or anticholinergic drug within 30 days. The participant has received any psychoneurotic agent or antiemetic medication of dopamine agonist within 14 days. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for &gt;= 14 days may be included in the study. The participant has previously received a catecholOmethyltransferase (COMT) inhibitor, droxidopa, zonisamide or istradefylline. The participant is required to take any of the excluded medications or treatments. The participant whose diagonosis of Parkinson's disease is ruled out by elective dopamine transporter scintigraphy. The participant has laboratory data meeting any of the following at the start: Creatinine &gt;= 2 x upper limit of normal (ULN) Total bilirubin &gt;= 2 x ULN ALT or AST &gt;= 1.5 x ULN ALP &gt;= 3 x ULN The participant has received any of the excludeded medications or treatments</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>